Dr. Sridhar Ganesan (DIN: 06819026) has been re-appointed as Managing Director of the Company
Term: Two years, effective from August 25, 2026 to August 24, 2028
Subject to approval of shareholders at the ensuing Annual General Meeting
Profile: Over 35 years of global leadership experience in the pharmaceutical industry with expertise spanning profit centre management, global marketing, international business development, project planning and implementation, production, new product development, quality assurance, and factory management
Has held leadership positions across various international assignments with extensive experience in South Asia, the Middle East and Africa
Currently provides strategic leadership in driving the Company's growth and expanding its global footprint
No relationships with other directors disclosed
Appointment of Whole-Time Director
Mr. D. Muralidharan (DIN: 08301904) has been appointed as Whole-Time Director of the Company
Term: Two years, effective from August 12, 2026 to August 11, 2028
Subject to approval of shareholders at the ensuing Annual General Meeting
Will continue serving as Chief Financial Officer (CFO) of the Company in addition to the Whole-Time Director role
Profile: Seasoned finance professional serving as CFO since February 19, 2016
Academic credentials: Bachelor's degree in Commerce (B.Com), Associate Membership of the Institute of Company Secretaries of India (ICSI), and Cost & Management Accountant qualification from Institute of Cost Accountants of India (ICMAI)
Member of the Risk Management Committee of the Company
